Even when diagnosed early, triple-negative breast cancer (TNBC) has a higher mortality rate compared with other breast cancer ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in ...

Topline results were announced from a phase 3 trial investigating a subcutaneous formulation of pembrolizumab, a programmed death receptor-1-blocking antibody, with berahyaluronidase alfa ...

Immutep Ltd (AU:IMM) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Pembrolizumab plus fulvestrant provided disease control in 50% of patients with ER-positive, HER2-negative metastatic breast cancer.

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck’s anti-PD-1 therapy, available for intravenous use as KEYTRUDA ®, together with ...

Lenvatinib plus pembrolizumab did not provide benefits over chemotherapy in the overall study cohort, but the combination did provide benefits in subgroups of patients.

During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate ...

There is a commercial arrangement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] for ...